CME webinar: Addiction Care for the Non-Addiction Provider Part 4 – Overview of Management and Available Resources
Jan. 2022Education/Webinars
"Please join us for a live, CME-accredited webinar Wednesday, March 23, from noon to 1 p.m. Michael Lynch, MD, Medical Director, Pittsburgh Poison Center; Medical Director, UPMC Health Plan Substance Use Disorder Services; and Assistant Professor of Emergency Medicine, Toxicology, Pediatrics, and Addiction at the University of Pittsburgh, will summarize the continuum of care for a patient with a substance use disorder (SUD) in an outpatient setting, including available resources to assist non-addiction providers with meeting the needs of these patients. This will be part 4 of a 4-part series.
During the program, Dr. Lynch will:
Register today at upmchp.us/ac4. This webinar will be recorded.
You may earn continuing medical education credits for attending this event.*
*Provider is responsible for verifying CME eligibility. This activity is approved for the following credit: AMA PRA Category 1 Credit™, ANCC, and ASWB. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity."
During the program, Dr. Lynch will:
- Present data regarding the prevalence and impact of SUDs on society and health care.
- Provide an overview of feasible screening, brief intervention, and referral to treatment processes, including reimbursement opportunities.
- Review basic medical management principles for patients with SUDs.
- Describe existing support and referral resources available to Pennsylvania providers to connect patients to ongoing care.
Register today at upmchp.us/ac4. This webinar will be recorded.
You may earn continuing medical education credits for attending this event.*
*Provider is responsible for verifying CME eligibility. This activity is approved for the following credit: AMA PRA Category 1 Credit™, ANCC, and ASWB. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity."
Recent Announcements
Voluntary nationwide recall: Famotidine (Fresenius – November)
Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.Nov. 2025Pharmacy Updates
Medicaid provider update: High-cost Medicaid drug billing
Billing requirements for Medicaid-covered drugsNov. 2025Important Notices
Training Webinar: Conversio Health COPD Management Program
Please join us for a live training webinar for primary care providers and pulmonologists by UPMC Health Plan that will provide an overview of a comprehensive COPD management program from Conversio Health.Nov. 2025Education/Webinars